CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,151 enrolled
Drug / intervention
Fenofibrate 145 mg +1 moredrug
Likely dose
Fenofibrate 145 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03439345
NCT03439345Phase 4Completed
CompareCT.gov

A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes

University of Oxford·interventional·Posted Feb 20, 2018·Updated May 14, 2025

In Brief

A Phase 4 clinical trial evaluating Fenofibrate 145 mg and Placebo Oral Tablet for Diabetic Retinopathy. Completed, enrolled 1,151 participants across 16 sites.

Detailed Summary

LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesUnited Kingdom
CollaboratorsNational Institute for Health Research, United Kingdom, University of Glasgow, University of Aberdeen, University of Dundee, University of Edinburgh, NHS Scotland Diabetic Retinopathy Screening Collaborative

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedFeb 20, 2018
Enrollment StartJul 23, 2018
Primary CompletionNov 17, 2023
Study CompletionFeb 16, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 8.4 years ago

Interventions

Fenofibrate 145 mgdrug

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

Placebo Oral Tabletdrug

One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)